Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Allarity Therapeutics (ALLR) Operating Expenses (2024 - 2025)

Allarity Therapeutics' Operating Expenses history spans 2 years, with the latest figure at $3.2 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 55.75% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $12.9 million, down 52.55%, while the annual FY2025 figure was $12.9 million, 52.55% down from the prior year.
  • Operating Expenses reached $3.2 million in Q4 2025 per ALLR's latest filing, up from $2.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $12.3 million in Q3 2024 to a low of $2.5 million in Q3 2025.